This content is for healthcare professionals only.

This activity is funded by an independent medical education grant from Astellas Pharma Inc. and Seagen Inc.

This activity is jointly provided by USF Health and touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues

    Downloads
    Slides
    Practice Aid
    Slides
    Practice Aid
    Slides
    Practice Aid
    Slides
    Practice Aid
    Slides
    Practice Aid
    Slides
    Practice Aid
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr Axel Merseburger

    University Hospital Schleswig-Holstein, Campus Lübeck, Germany

    Dr Axel Merseburger is a professor of urology and chairman of the Department of Urology at University Hospital Schleswig-Holstein, Campus Lübeck, Germany. He is trained in all aspects of open and endoscopic urology and has a specific interest in laparoscopic and robotic-assisted surgery, particularly for the management of prostate, renal and bladder cancer. read more

    Dr Merseburger’s research activity encompasses both molecular and clinical aspects of uro-oncology, focusing on biomarkers and prognostic factors for prostate cancer, renal cell carcinoma and transitional cell carcinoma. He is principal investigator in multiple phase II and III uro-oncology clinical trials.

    Dr Merseburger is a member of various uro-oncology organizations; he is chairman of the European Scholarship Programme of the European Association of Urology (EAU) and was the chairman of the EAU Guideline Group for Laser Technologies. He is a reviewer and editorial board member for several urology and oncology journals, and has published widely in the field, having authored or co-authored over 300 peer-reviewed articles.

    Dr Axel Merseburger discloses: Advisory board or panel fees from Astellas, Bayer, Ipsen, Janssen, Merck, MSD, Pfizer, Recordati, Roche, Takeda and Telix. Speaker’s bureau fees from Astellas, Bayer, Ipsen, Janssen, Merck, MSD, Pfizer, Recordati, Roche, Takeda and Telix.
    Dr André Fay

    PUCRS School of Medicine, Porto Alegre, Brazil

    Dr André Fay is a medical oncologist specializing in genitourinary (GU) malignancies and a professor of medicine at PUCRS School of Medicine, Porto Alegre, Brazil. He is chief of the fellowship programme and leader of GU oncology at PUCRS Hospital in Porto Alegre, Brazil. read more

    Dr Fay has trained at the Dana-Farber Cancer Institute, Boston, MA, USA, as a research fellow working with clinical and translational research in GU oncology. He continues the collaboration with the Dana-Farber Cancer Institute as a visiting scientist participating in different research projects.

    Dr Fay is the principal investigator of investigator-initiated and industry-sponsored phase II and phase III trials on GU malignancies. He is part of the steering committee for GU cancers in the Latin American Cooperative Oncology Group. This cooperative group is creating opportunities for clinical and translational research in Brazil and Latin America. Dr Fay is also one of the founders and the scientific director of BIO education, a platform committed to continuous medical education in Brazil and Latin America.

    Dr André Fay discloses: Advisory Board or Panel fees from AstraZeneca, Ipsen, Janssen, MSD, Novartis and Roche. Grants/research Support from Foundation Medicine. Stock/shareholder (self-managed) in Bio Pharma.
    Ms Maria Lapuente

    St Bartholomew’s Hospital, London, UK

    Ms Maria Lapuente is a lead oncology research nurse at St Bartholomew’s Hospital in London, UK. She has more than 10 years of experience in oncology, with over 6 years in cancer research. Ms Lapuente specializes in antibody–drug conjugate therapies and immunotherapy treatments, particularly in phase I and II combination trials. read more

    Ms Lapuente is a member of the Experimental Cancer Medicine Centres Patient and Public Involvement Group at St Bartholomew’s Hospital, focusing on promoting diversity, equity and inclusion within clinical trials. She has recently been appointed as a senior Cancer Research UK nurse at St Bartholomew’s Hospital to raise awareness and recruitment on clinical trials.

    Ms Maria Lapuente has no relevant financial disclosures in relation to this educational activity.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    Start activity
     
    Videos Take CE/CME Test
    Bladder Cancer, Genitourinary Cancer, Immunotherapy CE/CME accredited

    touchPANEL DISCUSSION
    A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity. Close

    Adverse event identification and management in locally advanced/metastatic urothelial carcinoma

    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Spanish, Brazilian Portuguese.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Identify adverse events promptly in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
    • Use appropriate management strategies for the adverse events that arise in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
    • Apply a multidisciplinary approach to the identification and management of adverse events in patients receiving immunotherapy or targeted therapy for locally advanced/metastatic urothelial carcinoma
    Overview

    In this activity, an oncologist, urologist and nurse specializing in the management of patients with urothelial carcinoma provide their perspectives on the identification and management of adverse events linked to immunotherapies and targeted therapies, with a focus on antibody–drug conjugates, fibroblast growth factor receptor inhibitors and immune checkpoint inhibitors. The discussion is guided by pre-canvassed questions provided by healthcare professionals involved in the management of patients with urothelial carcinoma.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    This activity has been designed to meet the educational needs of oncologists, urologists and oncology nurses involved in the management of urothelial carcinoma.

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Dr Axel Merseburger discloses: Advisory board or panel fees from Astellas, Bayer, Ipsen, Janssen, Merck, MSD, Pfizer, Recordati, Roche, Takeda and Telix. Speaker’s bureau fees from Astellas, Bayer, Ipsen, Janssen, Merck, MSD, Pfizer, Recordati, Roche, Takeda and Telix.

    Dr André Fay discloses: Advisory Board or Panel fees from AstraZeneca, Ipsen, Janssen, MSD, Novartis and Roche. Grants/research Support from Foundation Medicine. Stock/shareholder (self-managed) in Bio Pharma.

    Ms Maria Lapuente has no relevant financial disclosures in relation to this educational activity.

    Content reviewer

    Carolina Leon – APRN has no relevant financial relationships to disclose.

    Touch Medical Directors

    Hannah Fisher has no financial interests/relationships or affiliations in relation to this activity.

    Gregory Philp discloses: Employee or independent contractor relationship: Oxford Pharmagenesis/AstraZeneca (Relationships Terminated)

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu.

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Nurses

    USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    A maximum of 1.0 contact hour may be earned by learners who successfully complete this  continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

    Date of original release: 31 May 2023. Date credits expire: 31 May 2024.

    If you have any questions regarding credit please contact cpdsupport@usf.edu.

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Spanish, Brazilian Portuguese.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchMDT

    Uncharted territory: Introducing novel immunotherapeutic approaches for metastatic NSCLC without driver mutations

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer

    GO TO HUB

    touchPANEL DISCUSSION

    Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations?

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Neeraj Agarwal, ESMO 2021: Results of Expanded Cohort 6 of the COSMIC-021 Study

    GO TO HUB

    JOURNALS

    First-line Systemic Therapy in Patients Ineligible (‘Unfit’) to Receive a Cisplatin-based Regimen – Literature Review, Recommendations and Potential Use of Vinflunine in Combination or as Monotherapy

    GO TO ARTICLE

    JOURNALS

    Fiducial Markers in Image-guided Radiotherapy of the Prostate

    GO TO ARTICLE

    Topics covered in this activity

    Bladder Cancer / Genitourinary Cancer / Immunotherapy
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 8 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from Astellas Pharma Inc. and
    Seagen Inc. This activity is jointly provided by USF Health and touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Date of original release: 31 May 2023. Date credits expire: 31 May 2024.

    Claim Credit
    touchPANEL DISCUSSION
    Adverse event identification and management in locally advanced/metastatic urothelial carcinoma
    1.0 CE/CME credit
    Question 1/5
    You are treating your patient with metastatic urothelial carcinoma with erdafitinib. Which of the following monitoring strategies do you incorporate into their follow-up?

    Erdafitinib can cause an increase in phosphate levels and therefore serum phosphate levels should be assessed 14 to 21 days after initiating treatment and monthly thereafter.

    Reference

    FDA. Erdafitinib Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212018s005lbl.pdf (accessed 9 May 2023).

    Question 2/5
    Your patient with urothelial carcinoma has received 10 cycles of treatment with pembrolizumab and has tolerated the treatment with no reported side effects apart from fatigue. What would you do next with regards to monitoring for adverse events?

    In contrast with most treatment-related adverse events, immune-related adverse events can occur at any point during or beyond 6–12 months after treatment.1 Hepatitis and increased levels of ALT/AST are reported adverse events in patients receiving treatment with pembrolizumab.2 Despite a patient’s previous good tolerance of treatment, it is recommended to monitor liver function at the start of treatment with pembrolizumab and periodically during treatment.2

    Abbreviations

    ALT, alanine transaminase; AST, aspartate transferase.

    References

    1. Brahmer JR, et al. J Immunother Cancer. 2021;9:e002435.
    2. EMA. Pembrolizumab summary of product characteristics. Available at: www.ema.europa.eu/en (accessed 9 May 2023).
    Question 3/5
    Your patient with locally advanced urothelial carcinoma is undergoing treatment with enfortumab vedotin. During routine monitoring, a blood glucose level of >250 mg/dL is reported. How would you proceed with managing this patient?

    Hyperglycaemia is a reported adverse event of special interest in patients receiving treatment with enfortumab vedotin. For patients with a blood glucose level of >250 mg/dL, it is recommended that treatment is withheld until blood glucose has dropped below 250 mg/dL.

    Reference

    EMA. Enfortumab vedotin Summary of Product Characteristics. Available from: www.ema.europa.eu/en (accessed 9 May 2023).

    Question 4/5
    Your patient with metastatic urothelial carcinoma is receiving treatment with sacituzumab govitecan. Which of the following should you give the patient to take home in order to support the management of possible side effects?

    In clinical trials, diarrhoea occurred in 65% of all patients treated with sacituzumab govitecan. At the onset of diarrhoea, loperamide should be promptly initiated if there is no infectious cause.

    Reference

    FDA. Sacituzumab govitecan Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf (accessed 9 May 2023).

    Question 5/5
    You are treating a patient with erdafitinib. Which of the following specialists would you include in the multidisciplinary team involved in the routine monitoring of your patient?

    Erdafitinib can cause central serous retinopathy/retinal pigment epithelial detachment. It is therefore recommended that patients with urothelial carcinoma receiving treatment with erdafitinib are routinely monitored by an ophthalmologist during treatment, including visual acuity tests, fundoscopy, slit lamp examination and optical coherence tomography.

    Reference

    FDA. Erdafitinib Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212018s005lbl.pdf (accessed 9 May 2023).

    Back to Activity

    You may also be interested in...

    touchEXPERT OPINIONS

    Guideline-based treatment of recurrent/metastatic cervical cancer

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchMDT

    Optimizing the patient journey in CSCC through multidisciplinary collaboration

    This activity is CE/CME accredited
    LAUNCH ACTIVITY
    Morgan Rouprêt

    CONFERENCE HUB

    Morgan Rouprêt, ESOU22: Highlights from the Conference

    GO TO HUB

    JOURNALS

    Immunotherapy in Advanced Prostate Cancer

    GO TO ARTICLE

    CONFERENCE HUB

    Arlene Siefker-Radtke, ESMO 2019 – KEYNOTE-866 Phase III trial in bladder cancer

    GO TO HUB

    JOURNALS

    Single Case of a Complete Response in a Metastatic Urothelial Carcinoma Patient Treated with Zoptarelin Doxorubicin

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from Astellas Pharma Inc. and
    Seagen Inc. This activity is jointly provided by USF Health and touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Date of original release: 31 May 2023. Date credits expire: 31 May 2024.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72